Derginin
Derginin is a semi-synthetic derivative of the anti-tumor antibiotic dactinomycin, also known as actinomycin D. It is produced through a process that involves the chemical modification of the naturally occurring compound. Dactinomycin is a powerful cytotoxic agent that works by intercalating with DNA and inhibiting the process of transcription.
Researchers have modified the structure of dactinomycin to produce derginin, which is thought to be less toxic
Studies have shown that derginin is active against a range of cancer cell lines, including those resistant
Clinical trials are necessary to fully evaluate the safety and efficacy of derginin as a cancer treatment.
Further research is required to fully understand the therapeutic potential of derginin and to establish its